Digital therapeutics startup Neuroglee raises $10M to help people with neurodegenerative conditions

Neuroglee Therapeutics, a startup developing digital therapeutics for people with neurodegenerative diseases, has raised a $10 million Series A led by Openspace Ventures and EDBI. The funding will be used to launch virtual neurology clinics and to support Neuroglee’s move to Boston. Other participants included Ramen Singh, the former chief executive officer of Mundipharma; Biofourmis co-founders Kuldeep Singh Rajput and Wendou Liu; and Eisai Co., the Japanese pharmaceutical that led Neuroglee’s last round last year.

In an email, founder and chief executive officer Aniket Singh Rajput told TechCrunch that the company is moving to Boston because the city “is one of the largest digital health hubs in the world. As a company devoted to developing our first line of solutions for treating mild cognitive impairment related to difficult-to-treat neurodegenerative conditions such as Alzheimer’s disease, we believe Boston will offer us the strategic support in order to do so.”

Neuroglee and the Mayo Clinic are currently working together on a new platform called Neuroglee Connect. Based on the Mayo Clinic’s 10-day in-person program HABIT (Health Action to Benefit Independence and Thinking) for people with mild cognitive impairment from possible neurodegenerative conditions, Neuroglee’s technology will enable HABIT to scale, making it available to patients and caregivers in their homes. Neuroglee Connect users will also have access to health navigators who are available 24 hours and clinical care teams for assessments and interventions.

Neuroglee’s product pipeline also includes digital therapeutics for Parkinson’s disease and strokes.

Since Neuroglee’s previous funding announcement in December 2020, Rajput said it has hit milestones like the successful product development of NG-001, its prescription digital therapy software for Alzheimer’s, and began work on its proof-of-concept study to earn NG-001 a Breakthrough Designation from the Federal Drug Administration.

Neuroglee’s adaptive learning tech uses machine learning and biomarkers related to cognitive function, mood and behavior to automatically personalize therapy plans for each patient, who access the software through a smartphone or tablet.

“For example, adjustments will be made to the number and type of tasks and games that are offered, based on the speed of the patient’s finger movements, time to complete games or tasks, and their facial expression identified through the device camera,” said Rajput. “The solution also incorporates reminiscence therapy, which uses images from the patient’s past to evoke positive memories and emotions, which have been shown to improve cognitive functioning.”

,Neuroglee Therapeutics, a startup developing digital therapeutics for people with neurodegenerative diseases, has raised a $10 million Series A led by Openspace Ventures and EDBI. The funding will be used to launch virtual neurology clinics and to support Neuroglee’s move to Boston. Other participants included Ramen Singh, the former chief executive officer of Mundipharma; Biofourmis